Induction effects of ritonavir: implications for drug interactions. - Wikidata - thesis-toulmin - TriplyDB

Induction effects of ritonavir: implications for drug interactions.

Induction effects of ritonavir: implications for drug interactions.

http://www.wikidata.org/entity/Q37199533

about

Managing drug interactions in HIV-infected adults with comorbid illness Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.Prescription long-term opioid use in HIV-infected patients Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Understanding the pharmacokinetics of Coartem.Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.Drug interactions between antiretrovirals and hormonal contraceptives.Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.Pharmacokinetic enhancers in HIV therapeutics.Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.Darunavir/cobicistat once daily for the treatment of HIV.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers.Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity Effect of Liver Disease on Hepatic Transporter Expression and Function.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.

P2860

Q26825406-9D1DC00E-0DAC-47C9-867E-5C413E8650FC Q27677369-49BB9646-C744-471D-BC78-6877CC24810F Q30249162-23669BAA-BD3D-4091-B04E-93D94443F775 Q33400092-890DF253-EB10-4FB7-AC0C-3F06CF8F4BB4 Q33680234-09A437E9-F810-4F3A-9039-7A1FEE6AD5D7 Q34290041-E0E4370B-5E83-4849-8E87-E113A2BC9E4B Q34529127-4823DA9B-31DD-487B-B4C1-8011B77881AE Q34596882-50EC0BAE-F4A4-4362-B242-9DD66F0EA0A7 Q35120618-73AA0D2E-7BFA-4775-AE44-3C65EFB97131 Q35219167-EE6BACA9-D487-42D4-B979-FB59A5DBFCE0 Q35771822-9DE87DB6-F665-4E15-B8CF-274EF32A3858 Q35883504-53A0BC92-D020-4F45-813C-6BB6E29CCBBF Q36018600-93254681-4108-474E-B357-6C9EFBF1BDDC Q36125460-BC0BFD09-F6B0-4CF3-B4D8-C27CAE05C562 Q36144257-044CEFDC-D4C0-4588-9758-0CC0B852074B Q36359372-B8CB3821-E077-4348-AA28-A5576F84330B Q36969787-1F5A116A-B281-489F-868A-423F1652DAA8 Q37067118-49D2E5F1-337A-49D1-B621-DE8337204A98 Q37113947-2431B2B5-92FC-4502-8E66-7CDE186BC2DA Q37193089-E47F0513-0981-43CC-8610-E79C2FC54BA1 Q37298255-18A6B250-B7D8-4C6C-B53A-6D491ED8C593 Q37321441-E287109B-7237-4A69-9DAD-DD81F1824450 Q37325606-AD0B1627-73C1-4F8B-BDDD-F2D8ED9D70F6 Q37383289-A20D31CA-0CEA-42C3-A1E5-F2FAC07B8C83 Q37405336-8703A16F-BE95-4F5C-80E7-E8B337DB98D4 Q37481442-A1D846D8-4A30-4476-996F-925F2BDBE9D5 Q37631771-AC2E201A-23E5-48B8-8CD5-CA18351A8458 Q37900614-926E5F75-283A-46B9-8FA9-547623B82D20 Q38083080-69AC8ED3-1891-412C-BE3C-82D84636970A Q38087555-4E8300A3-0CCA-40A8-A39A-9507ACEC5C5B Q38155450-52678BC3-7C33-4E93-8147-B013D7D81E75 Q38244014-1EB21466-AE6C-46D7-869D-B0F7466FB55F Q38261574-97F98D49-7FA7-4913-9A4D-E56BCF4ACEF0 Q38377264-81AE100E-F6D4-4C4B-B3B1-CCD069488C15 Q38472696-0A996491-BCB2-4E88-A30B-AF041697DF2A Q38719799-6E95464B-A304-496D-BD25-17BA7971D7C9 Q38800976-AD589D76-8B47-46EB-BF14-7856FEECE422 Q38806803-F02DC189-8E76-4D35-A0AC-8E1E7FF9F6A8 Q38808182-D34AB344-5957-49CE-AD04-14BE8117FE16 Q38929010-13363B9F-3063-48C1-B8CC-6B2062A2DE37

P2860

Induction effects of ritonavir: implications for drug interactions.

http://www.wikidata.org/entity/Q37199533

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Induction effects of ritonavir: implications for drug interactions.

@en

Induction effects of ritonavir: implications for drug interactions.

@nl

type

label

Induction effects of ritonavir: implications for drug interactions.

@en

Induction effects of ritonavir: implications for drug interactions.

@nl

prefLabel

Induction effects of ritonavir: implications for drug interactions.

@en

Induction effects of ritonavir: implications for drug interactions.

@nl

P1433

Q37199533-D1B019A3-BCBC-4340-BB73-2CC704E9333E

P1476

Q37199533-161AA515-5127-4104-98E6-6BACF8D1A6CF

P2093

Q37199533-1800012E-50E5-4565-B557-ACD9E6D25D41

Q37199533-189C33CC-F137-4445-96EE-B1A4945A1FF7

Q37199533-9D14BE47-1C33-41A1-8AE5-950552CE44B1

P2860

Q37199533-028881B0-0B01-491F-95B2-5D121031C32A

Q37199533-0394E7F5-8B4B-40C1-9C99-51D590A5B138

Q37199533-0A52B5EA-9562-452B-8094-8DD411FA950D

Q37199533-0B0576A4-72A3-4D9B-ABA4-8ECB39EBFA5A

Q37199533-141380F9-963A-42A4-8191-91111797EADC

Q37199533-1A2370A1-7355-4705-A2CB-6668088F02FB

Q37199533-27F3AC3F-7741-462A-9A8A-40B7DDD11231

Q37199533-2898EB4E-E4E3-49FC-9AEF-98C8DB45E887

Q37199533-28F4BFC4-ED91-4D90-A652-7B42D4E7DCC8

Q37199533-298AAA6A-3115-492A-B6BE-6E02244C4229

P304

Q37199533-5B5BE374-5425-4E5E-B949-235FFDE62115

P31

Q37199533-18F412E4-0AAB-4287-A0BD-C7E44D328868

P356

Q37199533-84AE8F4E-EA7B-44C4-B31A-876A1868A192

P407

Q37199533-77E05838-F512-4162-9DE1-B5865ADCEE79

P433

Q37199533-E00A1991-FD47-471D-AA05-5D8C43AAD6B2

P478

Q37199533-04CBC745-0EC8-4329-B3F7-EEEECC4F1037

P577

Q37199533-14721A24-C12F-4E45-91E7-F06FF6723D30

P698

Q37199533-E4CEE744-438C-4BDE-A1D5-F8AF63C51D77

P356

P1433

Annals of Pharmacotherapy

P1476

Induction effects of ritonavir: implications for drug interactions.

@en

P2093

Christine A Hughes

http://www.w3.org/2001/XMLSchema#string

Erin M Yakiwchuk

http://www.w3.org/2001/XMLSchema#string

Michelle M Foisy

http://www.w3.org/2001/XMLSchema#string

P2860

Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study

Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers

Decreased methadone effect after ritonavir initiation

Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.

Cytochrome P-450 3A4: regulation and role in drug metabolism.

Interactions among drugs for HIV and opportunistic infections.

Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.

Cytochromes P450 and metabolism of xenobiotics.

Pharmacogenetics of warfarin elimination and its clinical implications.

P304

1048-1059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1K615

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18577765

http://www.w3.org/2001/XMLSchema#string